---
format:
  revealjs:
    spotlight: true
    touch: true
    controls: true
    pointer: true
    center-title-slide: false
    transition: fade
    transition-speed: fast
    scrollable: true
    slide-number: true
    incremental: false
    multiplex: true
    chalkboard: true
    theme: [default, custom.scss]
    filters:
     - highlight-text
bibliography: references.bib
lightbox: true
csl: diagnostic-microbiology-and-infectious-disease.csl
revealjs-plugins:
  - pointer
filters:
  - highlight-text
---

## Principles of Antibiotic Therapy

<br> <br>

Russell E. Lewis <br> Associate Professor of Infectious Diseases <br> Department of Molecular Medicine <br> University of Padua

<br> {{< fa solid envelope size=1x >}} russelledward.lewis\@unipd.it <br> {{< fa brands github size=1x >}} https://github.com/Russlewisbo

![](University_of_Padua_seal.svg){fig-align="left" width="75"}

## Antibiotics- Medical Miracles

![](resistance.jpg){fig-align="center"}

## Mortality reduction with antibiotic therapy {.smaller}

<br>

<br>

+------------------------------+--------------------+----------------+--------------+
| Disease                      | Pre-antibiotic era | Antibiotic era | Change       |
+==============================+====================+================+==============+
| Community-acquired pneumonia | \~ 35%             | \~ 10%         | -25%         |
+------------------------------+--------------------+----------------+--------------+
| Nosocomial pneumonia         | \~ 60%             | \~ 30%         | -30%         |
+------------------------------+--------------------+----------------+--------------+
| Bacterial endocarditis       | \~ 100%            | \~ 25%         | -75%         |
+------------------------------+--------------------+----------------+--------------+
| Gram-negative bacteremia     | \~ 70%             | \~ 10%         | -60%         |
+------------------------------+--------------------+----------------+--------------+
| Bacterial meningitis         | \> 80%             | \< 20%         | -60%         |
+------------------------------+--------------------+----------------+--------------+
| Skin infection               | \~ 11%             | \< 0.5%        | -10%         |
+------------------------------+--------------------+----------------+--------------+

<br>

::: footer
[@spellberg2025]
:::

## Antibiotics: <br> Essential for practice of modern medicine {background-image="images/antibiotic-resistance.jpg" background-opacity="0.3"}

<br>

-   Enable complicated and deeply-invasive surgery

-   Aggressive chemotherapy for cancer

-   Fundemental aspects of critical care

    -   e.g., central venous catheters, mechanical ventilation

-   Care for premature infants

-   Solid organ and stem cell transplantation

-   **Antibiotics created a revolution in the practice of medicine, transforming a primarily diagnostic-focused field to a *therapeutic, interventional* profession**

::: footer
[@spellberg2025]
:::

## Current antibiotic resistance statistics

<iframe src="https://vizhub.healthdata.org/microbe/?settings=eyIxIjoia2V5X2ZpbmRpbmdzIiwiMiI6ImJhciIsIjMiOiJhbXIiLCI0IjoyMiwiNSI6MSwiNiI6MywiNyI6MywiOCI6MSwiOSI6MSwiMTIiOjMsIjEzIjoxLCIxNCI6MSwiMTUiOjEsIjE2IjoxLCIxNyI6MywiMTgiOjIwMjEsIjE5IjpmYWxzZSwiMjAiOmZhbHNlLCIyMiI6MSwiMjQiOiJlbiIsIjI1Ijoic3luZHJvbWUiLCIyNiI6WzEsMiwzLDQsNSw2LDcsOCw5LDEwLDIyXSwiMjciOls0LDMxLDY0LDEwMywxMzcsMTU4LDE2Nl0sIjI4IjpbMiwzLDQsNSw2LDcsOCw5LDEwLDExLDEyLDEzXSwiMjkiOlsxLDJdLCIzMCI6WzEsNywxMSwxNywyMywyMl0sIjMxIjpbIjEtMSIsIjEtMiJdLCIzMiI6IjEtMSIsIjMzIjpbMSwyXX0=" width="100%" height="900px">

</iframe>

::: footer
Source: healthdata.org
:::

## World Health Organization (WHO) Pathogen Priority List

![](images/WHO.png){fig-align="center"}

## Methicillin-resistant Staphylococcus aureus (MRSA)

![](images/MRSA_ITALY.png){fig-align="center"}

## Carbapenem-resistant Enterobacterales (CRE)

![](images/CRE_ITALY.png){fig-align="center"}

## Multi-drug resistant (MDR) Acinetobacter baumannii

![](images/MDRABUAM_ITALY.png){fig-align="center"}

## Antibiotics are a societal trust

<br> <br> - Antibiotic overprescription is a *tragedy of the commons*: individual undertakes an action that they perceive to be in their own self-interest but that causes harm to society at large - When such an action is undertaken rarely, the harm to society is not noticeable - When it happens tens of millions of times per year, as with inappropriate antibiotic prescriptions, the collective harm to society can be catastrophic - Given the power of antibiotics to save lives, and the constant erosion of that power through their use, one of the most important functions of the physician is to serve as an expert *in the use and protection of antimicrobial agents*

## Antibiotic stewardship

+---------------------------------------+---------------------------------------+
| ![](images/steward1.png){width="800"} | ![](images/steward.jpeg){width="800"} |
+---------------------------------------+---------------------------------------+

## 10 Principles for effective use of <br> antibacterial therapy

::: nonincremental
1.  Accurate differential diagnosis

2.  Only use antibiotics when they alter the clinical course

3.  Empirically target microbes in differential diagnosis

4.  A lower threshold for empirical therapy should be used in critically-ill patients

5.  Host factors affect the spectrum of empirical therapy

6.  PK/PD principles impact optimal treatment

7.  De-escalate antibiotic therapy based on microbiology results and clinical (biomarker) responses

8.  If therapy is not working, consider source control or alternative diagnosis before broadening therapy

9.  Distiniguish new infection from failure of initial therapy

10. The duration of therapy should be as short as possible based on available evidence (shorter is better)
:::

## Principle #1: Accurate differential diagnosis

<br>

### What is the most tool for deciding to start antibiotic therapy?

A. Patient medical history

B. Physicial Exam

C. Radiological imaging (e.g., X-ray, CT or MRI)

D. Microbiological tests (e.g., culture, PCR, serology)

## Antibiotics are usually started empirically

```{dot}
digraph infection_timeline {
    // Graph settings
    rankdir=TB;
    splines=ortho;
    nodesep=0.6;
    ranksep=0.8;
    bgcolor="white";
    
    // Node defaults
    node [
        shape=box,
        style="filled,rounded",
        fillcolor="#F5DDD1",
        color="#F5DDD1",
        fontname="Arial",
        fontsize=14,
        width=3,
        height=0.6
    ];
    
    // Edge defaults
    edge [
        color="#D4764A",
        arrowsize=0.8,
        penwidth=1.5
    ];
    
    // Time labels (invisible nodes for positioning)
    node [shape=plaintext, fillcolor=transparent, color=transparent, fontcolor="#333333", fontsize=14];
    t0 [label="0h"];
    t1 [label="1h"];
    t24 [label="24h"];
    t48 [label="36-48h"];
    t72 [label="72h"];
    
    // Annotation labels - 200% larger (fontsize=24)
    node [fontsize=24, fontcolor="#333333"];
    empiric [label=<Begin <b>empiric therapy </b> for<br/>likely pathogens>];
    definitive [label=<Change to <b>definitive therapy</b><br/>for patient-specific pathogens>];
    
    // Main process nodes
    node [shape=box, style="filled,rounded", fillcolor="#F5DDD1", color="#F5DDD1", fontcolor="black", fontsize=14];
    suspect [label="Suspect infection"];
    culture [label="Culture suspected sites"];
    gram [label="Gram stain"];
    id [label="Identification"];
    suscept [label="Susceptibilities"];
    
    // Main flow
    suspect -> culture -> gram -> id -> suscept;
    
    // Position time labels and annotations using same rank
    {rank=same; suspect; t0}
    {rank=same; culture; t1; empiric}
    {rank=same; gram; t24}
    {rank=same; id; t48}
    {rank=same; suscept; t72; definitive}
    
    // Invisible edges for positioning
    edge [style=invis];
    empiric -> culture;
    culture -> t1;
    suspect -> t0;
    gram -> t24;
    id -> t48;
    suscept -> t72;
    t72 -> definitive;
}
```

## Antibiotics are usually started empirically {.smaller}

Antibiotics should only be started if the differential diagnosis includes likely invasive bacterial infections: 90-98% of upper respiratory tract infections are caused by viruses

![](images/URI.png){fig-align="center"}

Clinicians frequently *overestimate* the risk of bacterial infection

::: footer
[@chow2012]
:::

## Clinicians frequently *underestimate* the risks of antibiotic therapy

<br>

<br>

::: callout-warning
## 1 in 5 patients given antibiotic prescriptions are harmed by them because of adverse events or superinfections by resistant pathogens or *Clostridioides difficile*
:::

<br>

::: callout-warning
## Every additional 10 days of antibiotic therapy confers a 3% increased risk of an adverse drug effect
:::

<br>

The combination of fear from uncertainty of the diagnosis and lack of appreciation of how dangerous antibiotics can be is a particularly important driver of inappropriate prescriptions for upper respiratory tract illnesses in outpatient settings

::: footer
[@tamma2017b]
:::

## Association of adverse events with antibiotic use in hospitalized patients

![](images/adverseeffects.png){fig-align="center"}

::: footer
[@tamma2017b]
:::

## Positive cultures <br>are not always proof of infection {.smaller}

<br>

-   The presence of a positive culture in the absence of signs or symptoms of infection **should not** reflexively trigger antibiotic prescription.

-   In many cases, absent signs or symptoms of infection represent **colonization or contamination** and should not trigger treatment. <br> <br>

+-----------------------+-----------------------+---------------------------+------------------------------+-----------------------+
| Wound swabs           | Urine cultures        | Bronchial alveolar lavage | Respratory samples           | GI tract/stool        |
+=======================+=======================+===========================+==============================+=======================+
| ![](images/wound.png) | ![](images/urine.png) | ![](images/BAL.png)       | ![](images/nasal%20swab.png) | ![](images/stool.png) |
+-----------------------+-----------------------+---------------------------+------------------------------+-----------------------+

## Simple stewardship interventions

![](images/computer.png){fig-align="center"}

::: footer
[@luu2021]
:::

## Simple stewardship intervention- a big impact!\|

![](images/outcomes.png){fig-align="center"}

::: footer
[@luu2021]
:::

## Principle #2: Only use antibiotics when they alter the clinical course of patients

-   The administration of antibiotics should not be a reflexive response to infection, but rather should be incorporated into an overall, rational therapeutic plan for the patient.

-   Patients who lack bacterial infections cannot have their clinical course improved by antibiotics (as discussed in Principle #1).

    ![Chronic osteomyelitis with exposed bone](images/osteo.png){fig-align="center"}

## Ethical dilemmas for use of antimicrobial therapy

<br>

| End of life (comfort care) | Non-adherent HIV therapy |
|----------------------------|--------------------------|
| ![](images/terminal.png)   | ![](images/HIV.png)      |

## Principle #3: Empirically target microbes in differential diagnosis

## Know the spectrum of activity

+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------+
| -   Spectrum of activity of the empirical antiinfective agents prescribed should be tailored to cover the likely microbial flora that cause the diseases in the differential diagnosis | ![](images/Sanford.png)                        |
|                                                                                                                                                                                        |                                                |
|                                                                                                                                                                                        | [Sanford Guide](https://web.sanfordguide.com/) |
+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------+

## Basic principles of coverage {.smaller}

<br> <br>

+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------+
| Community infections                                                                                                                                                                      | Nosocomial infections                                                                                                                    |
+===========================================================================================================================================================================================+==========================================================================================================================================+
| Community-associated infections are infrequently caused by MDR gram-negative bacteria. <br> Empirical antibiotic coverage should not routinely considered                                 | More often caused by more resistant pathogens, and hence require coverage for P*seudomonas* or other nonfermenting gram-negative bacilli |
+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------+
| Avoid using routine methicillin-resistant *S. aureus* (MRSA) empirical therapy in patients who are unlikely to be infected with MRSA                                                      | Greater risk for MRSA, especially is patient has recently received antibiotic therapy                                                    |
+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------+
| Reserve the use of antimicrobials that can be used as last-line oral therapeutic options (e.g., fluoroquinolones) for infections for which there are no reasonable alternative therapies. | May require "frontline" used of lastline antibiotic if patient has risk factors for multidrug resistant infection                        |
+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------+

<br> Special circumstances creates exceptions: For example, community-acquired pneumonia and intraabdominal, skin, and urinary infections may be caused by *Pseudomonas* in patients with cystic fibrosis or with history of bronchiectasis, chronic dialysis patient, or patient with indwelling catheters or recent surgery.

## Principle #4: A lower threshold for empirical therapy should be used in critically-ill patients

![](images/ICU.png){fig-align="center" width="600"}

## Antibiotic timing is critical in septic shock

![](images/kumar.png){fig-align="center"}

::: footer
[@kumar2006]
:::

## Principle #5: Host factors affect the spectrum of empirical therapy

![](images/immunocompromise.png){fig-align="center"}

## Common immunocompromising conditions

+-------------------------+-------------------------------------------------------------------------------------+
| ![](images/patient.png) | 1.  Chronic diseases (e.g., type 1 diabetes, chronic obstructive pulmonary disease) |
|                         |                                                                                     |
|                         | 2.  Autoimmune diseases (e.g., lupus, rheumatoid arthritis)                         |
|                         |                                                                                     |
|                         | 3.  Genetic diseases (primary immunodeficiencies)                                   |
|                         |                                                                                     |
|                         | 4.  Cancer and/or chemotherapy                                                      |
|                         |                                                                                     |
|                         | 5.  Human immunodeficiency virus (HIV)                                              |
|                         |                                                                                     |
|                         | 6.  Solid organ or bone marrow transplant                                           |
|                         |                                                                                     |
|                         | 7.  Advanced age                                                                    |
|                         |                                                                                     |
|                         | 8.  Malnutrition                                                                    |
|                         |                                                                                     |
|                         | 9.  **Chronic use of corticosteroids or other immunosuppressive medications**       |
|                         |                                                                                     |
|                         | 10. Chronic infections                                                              |
|                         |                                                                                     |
|                         | 11. Smoking                                                                         |
+-------------------------+-------------------------------------------------------------------------------------+

## Glucocorticoids: <br>"Credit cards" of immunosuppressive therapy

![](images/glucocorticoids.png){fig-align="center" width="400"}

Dose-dependent increase in the risk of opportunistic infections \> 10 mg of prednisone equivalents (PEQ) per day for 2-4 weeks

::: aside
<br>

<br>

<br>

[@chastain2023]
:::

## Community acquired pneumonia (CAP) vs. <br> Pneumocystis jirovecii pneumonia (PCP)

+---------------------------------------+------------------------------------------+
| ![](images/PCP_xray.png){width="449"} | ![](images/PCP_CT.png){width="427"}      |
|                                       |                                          |
| Diffuse bilateral infiltrates         | Patchy areas of ground-glass attenuation |
+---------------------------------------+------------------------------------------+

## Principle #6: PK/PD principles impact optimal treatment

```{dot}
digraph G {
	fontname="Lato,Arial,sans-serif"
	node [fontname="Lato,Arial,sans-serif"]
	edge [fontname="Lato,Arial,sans-serif"]


patient -> PK;
drug -> PK;
intrinsic-> PD;
acquired -> PD;
inoculum -> PD;
PK -> PKPD;
PD -> PKPD;
PKPD -> microbiological;
microbiological -> clinical;

  clinical [shape=box, label="Clinical outcome"];
  microbiological [shape=box, label="Microbiological outcome"];
  PK [shape=oval, label="Pharmacokinetics (PK)"];
  PD [shape=oval, label="Pharmacodynamics (PD)"];
  PKPD [shape=oval, label="PK/PD"];
  patient [shape=none, label="Patient factors"];
  drug [shape=none, label="Drug factors"];
  intrinsic [shape=none, label="Intrinsic resistance"];
  acquired [shape=none, label="Acquired resistance"];
  inoculum [shape=none, label="Infection inoculum"];
}
```

::: aside
[@theuretzbacher2012]
:::

## Pharmacology of antimicrobials

```{dot}
digraph G {
 	rankdir=LR
 	fontname="Lato,Arial,sans-serif"
	node [fontname="Lato,Arial,sans-serif"]
	edge [fontname="Lato,Arial,sans-serif"]
 
  subgraph cluster_0 {
    style=filled;
    color=lightblue;
    node [style=filled,color=white];
    start -> dosing;
    dosing -> tissue;
    dosing -> infection;
    label = "Pharmacokinetics (PK)";
    graph [labelloc=a]
    
    
    
  }
  
    subgraph cluster_1 {
    line=black;
    style=filled;
    color=lightblue;
    node [style=filled,color=white];
  tissue->PD1
    infection-> PD2;
    label = "Pharmacodynamics (PD)";
  }
  
 
  start [shape=Box, label="Dosing regimen"];
  dosing [shape=rectangle, style=filled,color=yellow, label="Conc. vs. \n time in serum", xlabel=" \n    \n  \nAbsorption \nDistribution \nMetabolism \nElimination"];
  tissue [shape=rectangle, style=filled,color=white, label="Conc. vs. \n time in tissue"];
  infection [shape=rectangle, style=filled, color=white, label="Conc. vs. \n time at site of \n infection"];
  PD1 [shape=rectangle, label="Pharmacological or  \n toxicological effect"]; 
  PD2 [shape=rectangle, label="Antimicrobal effect \n vs. time"];
}


```

::: aside
[@craig_1998]
:::

## Key pharmacokinetic variables

<br>

![](images/AUC.png){fig-align="center"}

## Principle #7: De-escalate antibiotic therapy based on microbiology results and clinical (biomarker) responses

## Principle #8: If therapy is not working, consider source control or alternative diagnosis before broadening therapy

## Principle #9: Distiniguish new infection from failure of initial therapy

## Principle #10: The duration of therapy should be as short as possible based on available evidence (shorter is better)

## Common myths of antibiotic therapy

## Bactericidal antibiotics are more effective than bacteriostatic

## Oral therapy is less effective than IV for complex infections

## Combination therapy: *The good, the bad,...the ugly*

## Does combination therapy prevent resistance?

## References